Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK/Pozen Trexima update

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Pozen plans to submit an NDA in the third quarter for its migraine combination therapy Trexima (sumatriptan/naproxen) following a pre-NDA meeting with FDA. The firm also announced that Trexima showed statistically significant results for all primary endpoints in a second pivotal trial. Based on discussion at the pre-NDA meeting, Pozen "believes that no additional preclinical or clinical trials are necessary for submission," the firm says April 21. In the pivotal trial, Trexima showed superiority over its individual components with respect to pain-free response and pain relief. At the moment, Trexima appears to be Pozen's most promising product. The firm's other migraine agents, MT-100 and MT-300, are both "not approvable" at FDA. The agency recently postponed an MT-100 advisory committee...

You may also be interested in...

Health And Wellness Trademark Review 8 September, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Vitamin D And COVID-19 Studies: Prevention Benefits Suggested By Chicago Research

A study with nearly 500 patients with vitamin D levels tested within a year before receiving COVID-19 tests found subjects deficient in the nutrient had 1.77 greater chance of testing positive. Researchers say RCTs are needed to determine if broad population interventions are necessary.

Novocure Transforms Patient Support System During Pandemic

The company is running a pilot program to allow glioblastoma patients who use Novocure’s Optune Tumor Treating Fields device to download data from the device at home.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts